Vericel (NASDAQ:VCEL) Downgraded by Wall Street Zen to Hold

Key Points

• Wall Street Zen downgraded Vericel (NASDAQ:VCEL) from a "buy" to a "hold" in a report issued Saturday.
• Analysts remain mixed: MarketBeat's consensus is a Moderate Buy with a $58.50 target (four Buy, three Hold), while price targets range from Truist's $45 to HC Wainwright's $64.
• Vericel's latest quarter reported $0.45 EPS and $92.92M revenue—matching estimates and showing revenue up 23.3% YoY—yet the stock trades around $33.71 with a PE near 109.

Vericel (NASDAQ:VCEL - Get Free Report) was downgraded by research analysts at Wall Street Zen from a "buy" rating to a "hold" rating in a report issued on Saturday.

Several other research analysts have also commented on VCEL. Weiss Ratings reaffirmed a "hold (c-)" rating on shares of Vericel in a research report on Monday, December 29th. Truist Financial reduced their price target on shares of Vericel from $50.00 to $45.00 and set a "buy" rating for the company in a research report on Thursday, December 18th. HC Wainwright raised their price objective on shares of Vericel from $60.00 to $64.00 and gave the stock a "buy" rating in a research report on Friday, February 27th. Finally, Zacks Research cut shares of Vericel from a "strong-buy" rating to a "hold" rating in a report on Wednesday, November 12th. Four investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat, Vericel has a consensus rating of "Moderate Buy" and a consensus target price of $58.50.

Vericel Price Performance

NASDAQ VCEL opened at $33.71 on Friday. The company has a fifty day moving average of $36.80 and a two-hundred day moving average of $36.06. The company has a market capitalization of $1.71 billion, a PE ratio of 108.74 and a beta of 1.22. Vericel has a 1 year low of $29.24 and a 1 year high of $50.36.

Vericel (NASDAQ:VCEL - Get Free Report) last posted its earnings results on Thursday, February 26th. The biotechnology company reported $0.45 EPS for the quarter, hitting analysts' consensus estimates of $0.45. The business had revenue of $92.92 million for the quarter, compared to analysts' expectations of $92.66 million. Vericel had a return on equity of 5.17% and a net margin of 5.98%.The business's revenue was up 23.3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.38 earnings per share. On average, research analysts expect that Vericel will post 0.14 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in VCEL. Kestra Advisory Services LLC purchased a new position in Vericel during the fourth quarter worth about $27,000. Huntington National Bank lifted its position in Vericel by 51.3% in the third quarter. Huntington National Bank now owns 805 shares of the biotechnology company's stock valued at $25,000 after purchasing an additional 273 shares during the period. Quarry LP purchased a new stake in Vericel in the 4th quarter valued at approximately $31,000. Farther Finance Advisors LLC increased its position in Vericel by 116.5% during the 4th quarter. Farther Finance Advisors LLC now owns 970 shares of the biotechnology company's stock worth $35,000 after purchasing an additional 522 shares during the period. Finally, Abich Financial Wealth Management LLC acquired a new position in Vericel during the 3rd quarter worth approximately $31,000.

Vericel Company Profile

Vericel Corporation is a biotechnology company specializing in the development, manufacturing and commercialization of cell-based therapies for patients with severe diseases and conditions. The company's expertise lies in regenerative medicine, where it harnesses the power of autologous cell processing to create products designed to restore function and promote healing in damaged tissues.

Vericel currently markets two FDA-approved therapies. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is indicated for the repair of symptomatic cartilage defects of the knee in adult patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.